Tal Zaks. Moderna

The mR­NA uni­corn Mod­er­na has more ear­ly-stage hu­man da­ta it wants to show off — reach­ing new peaks in prov­ing the po­ten­tial

The whole mes­sen­ger RNA field has at­tract­ed bil­lions of dol­lars in pub­lic and pri­vate in­vestor cash gam­bled on the prospect of get­ting in on the ground floor. And this morn­ing Boston-based Mod­er­na, one of the lead­ers in the field, wants to show off a few more of the cards it has to play to prove to you that they’re re­al­ly in the game.

The whole hand, of course, has yet to be dealt. And there’s no telling who gets to walk with a share of the pot. But any cards on dis­play at this point — es­pe­cial­ly af­ter be­ing ac­cused of keep­ing its deck un­der lock and key — will at­tract plen­ty of at­ten­tion from some very wary, and wired, ob­servers.

“In terms of the com­plex­i­ty and un­met need,” says Tal Zaks, the chief med­ical of­fi­cer, “this is peak for what we’ve ac­com­plished.”

Mod­er­na has two Phase I stud­ies it wants to talk about now.

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.